Mainz Biomed NV, a specialist in cancer early detection diagnostics, has announced that its ColoAlert® test has received official registration from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This milestone allows the test, which detects tumor DNA biomarkers in stool samples, to be distributed throughout the UK. This regulatory approval follows a technology partnership with EDX Medical Group plc and aims to complement existing colorectal cancer screening programs, enhancing accessibility and participation in early cancer detection efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191700_de), on September 02, 2025, and is solely responsible for the information contained therein.